

Markus Eckstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/199887/publications.pdf>

Version: 2024-02-01

107
papers

1,981
citations

361413

20
h-index

377865

34
g-index

112
all docs

112
docs citations

112
times ranked

2231
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. <i>Journal of Clinical Pathology</i> , 2023, 76, 126-132.	2.0	7
2	Imaging, histopathological degree of degeneration and clinical findings – Do these correlate in patients with temporomandibular joint disorders. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022, 123, 353-357.	1.3	1
3	Impact of intraepithelial capillary loops and atypical vessels in confocal laser endomicroscopy for the diagnosis of laryngeal and hypopharyngeal squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 2029-2037.	1.6	5
4	Validation of a classification and scoring system for the diagnosis of laryngeal and pharyngeal squamous cell carcinomas by confocal laser endomicroscopy. <i>Brazilian Journal of Otorhinolaryngology</i> , 2022, 88, S26-S32.	1.0	3
5	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e9-63.e18.	1.6	5
6	Utility of stromal tumor infiltrating lymphocyte scoring (STILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e19-63.e26.	1.6	6
7	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
8	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 811200.	4.8	7
9	Systematic interpretation of confocal laser endomicroscopy: larynx and pharynx confocal imaging score. <i>Acta Otorhinolaryngologica Italica</i> , 2022, 42, 26-33.	1.5	5
10	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	1.6	7
11	Validity of tissue homogeneity in confocal laser endomicroscopy on the diagnosis of laryngeal and hypopharyngeal squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 4147-4156.	1.6	4
12	Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. <i>European Urology</i> , 2022, 81, 606-614.	1.9	6
13	Fast whole-slide cartography in colon cancer histology using superpixels and CNN classification. <i>Journal of Medical Imaging</i> , 2022, 9, 027501.	1.5	3
14	Acute systemic knockdown of <i>Atg7</i> is lethal and causes pancreatic destruction in shRNA transgenic mice. <i>Autophagy</i> , 2022, 18, 2880-2893.	9.1	3
15	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2022, 167, 13-22.	2.8	15
16	F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial. <i>Annals of Nuclear Medicine</i> , 2022, 36, 623-633.	2.2	3
17	Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts – A follow-up. <i>Cancer Medicine</i> , 2022, 11, 4743-4755.	2.8	16
18	Systematic classification of confocal laser endomicroscopy for the diagnosis of oral cavity carcinoma. <i>Oral Oncology</i> , 2022, 132, 105978.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.. Journal of Clinical Oncology, 2022, 40, 6064-6064.	1.6	2
20	POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer. Translational Oncology, 2021, 14, 100900.	3.7	9
21	Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy. Cells, 2021, 10, 159.	4.1	6
22	Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. , 2021, 9, e001845.		36
23	TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. Genes, 2021, 12, 230.	2.4	10
24	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. Current Drug Targets, 2021, 22, 162-170.	2.1	16
25	Intraoperative free margins assessment of oropharyngeal squamous cell carcinoma with confocal laser endomicroscopy: a pilot study. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4433-4439.	1.6	12
26	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. Cancers, 2021, 13, 1424.	3.7	21
27	Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer. Bladder Cancer, 2021, 7, 71-78.	0.4	0
28	Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer, 2021, 21, 314.	2.6	9
29	Endogenous Retroviralâ€“K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 657187.	2.8	16
30	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers, 2021, 13, 1959.	3.7	11
31	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. Cancers, 2021, 13, 2327.	3.7	8
32	KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 473.	2.5	5
33	High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Life, 2021, 11, 642.	2.4	3
34	Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta nonâ€“muscleâ€“invasive bladder cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 7890-7900.	3.6	7
35	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology, 2021, 157, 93-101.	1.0	6
36	IQGAP3, a YAP Target, Is Required for Proper Cell-Cycle Progression and Genome Stability. Molecular Cancer Research, 2021, 19, 1712-1726.	3.4	11

#	ARTICLE	IF	CITATIONS
37	Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. <i>Cells</i> , 2021, 10, 1796.	4.1	3
38	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	2.2	22
39	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. <i>World Journal of Urology</i> , 2021, 39, 4011-4019.	2.2	22
40	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6567-6578.	1.9	10
41	<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
42	MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2021, 12, 5066.	12.8	34
43	Feasibility of intraoperative assessment of safe surgical margins during laryngectomy with confocal laser endomicroscopy: A pilot study. <i>Auris Nasus Larynx</i> , 2021, 48, 764-769.	1.2	12
44	Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2021, 11, 17981.	3.3	9
45	Deep learning for diagnosis and survival prediction in soft tissue sarcoma. <i>Annals of Oncology</i> , 2021, 32, 1178-1187.	1.2	51
46	Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM Remodeling. <i>Cancer Research</i> , 2021, 81, 1552-1566.	0.9	26
47	Brain and Breast Cancer Cells with PTEN Loss of Function Reveal Enhanced Durotaxis and RHOB Dependent Amoeboid Migration Utilizing 3D Scaffolds and Aligned Microfiber Tracts. <i>Cancers</i> , 2021, 13, 5144.	3.7	4
48	Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer—Comparison of a Prospective Trial with a Revised Simulated Contouring Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 4653.	2.4	1
49	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	2.8	9
50	Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1063-1071.	2.0	7
51	CD137-reactive protein flare response predicts long-term efficacy to first-line anti-PD-1 based combination therapy in metastatic renal cell carcinoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1358.	3.8	15
52	Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13108.	4.1	5
53	Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC). <i>Pathology and Oncology Research</i> , 2020, 26, 1625-1632.	1.9	4
54	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. <i>Cancers</i> , 2020, 12, 2794.	3.7	17

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378.		51
56	Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. European Journal of Cancer, 2020, 140, 55-62.	2.8	23
57	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	1.9	57
58	High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 8407.	4.1	14
59	Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients. Cancers, 2020, 12, 2639.	3.7	5
60	Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 288.	8.6	11
61	CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. Cancers, 2020, 12, 1253.	3.7	21
62	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e629-e642.	1.9	8
63	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer, 2020, 20, 230.	2.6	24
64	EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. Cell Death and Disease, 2020, 11, 147.	6.3	58
65	Immunotherapy for urothelial cancer: from the diagnostic pathologistâ€™s point of view. Expert Opinion on Biological Therapy, 2020, 20, 539-544.	3.1	9
66	Same same but different: A Webâ€based deep learning application revealed classifying features for the histopathologic distinction of cortical malformations. Epilepsia, 2020, 61, 421-432.	5.1	17
67	Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas. Modern Pathology, 2020, 33, 1433-1442.	5.5	9
68	Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. European Urology, 2020, 78, 256-264.	1.9	96
69	Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. Cancers, 2020, 12, 763.	3.7	22
70	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. Journal of Clinical Medicine, 2020, 9, 994.	2.4	14
71	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
72	A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).. Journal of Clinical Oncology, 2020, 38, 6519-6519.	1.6	3

#	ARTICLE	IF	CITATIONS
73	PD1/PD-L1 Axis in Uro-oncology. <i>Current Drug Targets</i> , 2020, 21, 1293-1300.	2.1	6
74	Hrd in ovarian cancer: Defined today, evolving for the future.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18052-e18052.	1.6	1
75	DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 84, 1-7.	2.0	7
76	<sc>FOXM</sc>1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage <sc>pT</sc>1 non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 187-196.	2.5	19
77	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. <i>Future Oncology</i> , 2019, 15, 2199-2202.	2.4	14
78	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. <i>Histopathology</i> , 2019, 75, 865-875.	2.9	35
79	Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial). <i>Annals of Oncology</i> , 2019, 30, v456-v457.	1.2	2
80	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. <i>Annals of Translational Medicine</i> , 2019, 7, S135-S135.	1.7	13
81	Cpr126 (Adgrg6) is expressed in cell types known to be exposed to mechanical stimuli. <i>Annals of the New York Academy of Sciences</i> , 2019, 1456, 96-108.	3.8	15
82	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. <i>Laboratory Investigation</i> , 2019, 99, 1527-1534.	3.7	13
83	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	3.4	148
84	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , 2019, 12, 661-668.	3.7	16
85	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>Eur Urol</i> 2019;75:538-40. <i>European Urology</i> , 2019, 75, e162-e163.	1.9	2
86	Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients. <i>Cancers</i> , 2019, 11, 2029.	3.7	9
87	ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data. <i>Cancers</i> , 2019, 11, 1840.	3.7	15
88	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019, 106, 234-243.	2.8	75
89	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	1.7	77
90	Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer. <i>International Journal of Urology</i> , 2018, 25, 442-449.	1.0	17

#	ARTICLE	IF	CITATIONS
91	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 248-256.e2.	1.9	16
92	Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. <i>Translational Oncology</i> , 2018, 11, 467-476.	3.7	19
93	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 403-412.	4.2	54
94	Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. <i>Oncotarget</i> , 2018, 9, 25935-25945.	1.8	22
95	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. <i>Oncotarget</i> , 2018, 9, 15001-15014.	1.8	33
96	Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients. <i>Scientific Reports</i> , 2018, 8, 17693.	3.3	17
97	Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 530.e19-530.e27.	1.6	4
98	Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 6238-6248.	3.6	27
99	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. <i>Scientific Reports</i> , 2018, 8, 14383.	3.3	32
100	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3396.	4.1	35
101	Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer. <i>European Urology</i> , 2018, 74, 527-529.	1.9	16
102	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 267-274.	2.8	58
103	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. <i>Translational Oncology</i> , 2017, 10, 340-345.	3.7	22
104	ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. <i>Urologia Internationalis</i> , 2017, 98, 282-289.	1.3	30
105	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 272-294.	0.1	6
106	FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. <i>Oncotarget</i> , 2017, 8, 47595-47606.	1.8	16
107	The effects of an overnight holding of whole blood at room temperature on haemoglobin modification and <i>in vitro</i> markers of red blood cell aging. <i>Vox Sanguinis</i> , 2015, 108, 359-367.	1.5	11